Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature

Onderzoeksoutputpeer review

81 Citaten (Scopus)
806 Downloads (Pure)

Samenvatting

Targeted treatment of advanced non-small cell lung cancer patients with afatinib in EGFR mutation or crizotinib in ALK break positive patients results in profound tumor responses but inevitably induces resistance. In this review we present currently known resistance mechanisms for afatinib and crizotinib two recently approved drugs.

Resistance mechanisms identified for afatinib include c-MET amplification and the V8431 EGFR mutation. Expression of FURL increased IL6R/JAK/STAT signaling, enhanced interference with aerobic glycolysis and autophagy are associated with resistance to afatinib. Most common resistance mechanisms for ALK break positive cases are gatekeeper mutations in the ALK gene. Also activation of the EGFR pathway, KRAS mutations, the autophagy pathway and epithelial mesenchymal transition (EMT), have been associated with resistance. Many of the proposed resistance mechanisms need to be functionally studied to proof a causative relationship with resistance. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Originele taal-2English
Pagina's (van-tot)107-116
Aantal pagina's10
TijdschriftCritical Reviews in Oncology/Hematology
Volume100
DOI's
StatusPublished - apr.-2016

Citeer dit